Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "certificate of analysis"

Looking for quality documents?
external link icon
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington’s Disease Model
external link icon
Repligen Announces Market Launch of OPUS® 80R, Reinforces Technology Leadership in Pre-Packed Chromatography
- First and only available 80 cm diameter pre-packed column to address large-scale clinical and commercial-scale manufacturing of biological drugs -
WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its next-generation OPUS® column, the OPUS 80R, which is the largest pre-packed column on the market and is suitable for late-stage clinical into commercial-scale manufacturing of biological drugs. OPUS columns are used in downstream manufacturing processes, to purify biologics including monoclonal antibodies, recombinant proteins, vaccines and gene therapies. The OPUS product line is the industry’s broadest and most scalable with packed bed volumes now ranging from 50 microliters to 150 liters. The groundbreaking OPUS 80R columns are being highlighted in a Technology Workshop on March 21 st at the BioProcess International West
external link icon
Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
external link icon
Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity Ligands
WALTHAM, Mass., June 27, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced an agreement with Navigo Proteins GmbH (“Navigo”) for the advancement of exclusive novel affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. Under the terms of this agreement, Repligen and Navigo will co-develop a portfolio of next generation ligands, utilizing Navigo’s proprietary Precision Capturing™ technology platform. As part of the collaboration, Repligen receives intellectual property rights and exclusivity on all affinity ligands developed with Navigo, and Navigo receives a series of milestone and royalty payments.   
This formal agreement expands on a two-year relationship between Repligen and Navigo that has produced a best-in-class Protein A ligand with strong caustic stability and ultra-high binding capacity. Scale-up and validation for
external link icon
Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
external link icon
Repligen Provides Q2 FY2012 Corporate Update Regulatory Progress on SecreFlo™ and Record Sales of Bioprocessing Products
external link icon
Repligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of Potential Treatment for Spinal Muscular Atrophy
external link icon
Repligen Receives Additional Research Grants to Support Development of HDAC Inhibitors for Friedreich’s Ataxia and Huntington’s Disease
external link icon
Repligen Announces Acquisition of Chromatography Technology Platform "Plug and Play" Products Create Broad Opportunity in Biopharmaceutical Manufacturing
event icon
Viral vector N-1 intensification reduces seed train vessel number, media volume and time
The demand for gene therapy viral vectors requires manufacturing processes to scale up to 2000 L. Viral vector production at this scale requires a 9- to 12-day seed train with two to three seeding bioreactors, increasing the risk of failure and manufacturing cost. Perfusion-based cell culture intensification techniques shorten and simplify the seed train for recombinant proteins and monoclonal antibodies production by reducing time, equipment, bioreactor size and cost while increasing the potential number of batches per year. This webinar will discuss similar efficiency gains for three different viral vectors (lentivirus, AAV8 and AAV9) through intensification using KrosFlo® TFDF® Technology that resulted in reduce train vessel number, N-1 vessel size, media volume and time.